Credit Suisse Reports Decision Of Swiss Takeover Board - Quick Facts

In connection with the planned capital increase of Credit Suisse Group AG, on 14 November 2022, the Takeover Board resolved the syndicate of banks will be granted an exemption from the obligation to make an offer, provided that the number of registered shares of Credit Suisse Group AG exceeding the threshold is resold within six months of the threshold being exceeded. The decision is subject to the condition that no significant influence is exercised over Credit Suisse Group AG during the period in which the threshold is exceeded.

The fee payable by Credit Suisse AG, Deutsche Bank AG, Morgan Stanley & Co. International plc, RBC Europe, Société Générale, ABN AMRO Bank, Banco Santander S.A., Barclays Bank, BNP Paribas, Citigroup Global Markets Limited, Commerzbank, Credit Agricole Corporate and Investment Bank, Goldman Sachs International, ING Bank N.V., Intesa Sanpaolo, Keefe, Bruyette & Woods, Mediobanca Banca di Credito Finanziario, Merill Lynch International, SMBC Nikko Capital Market Limited and Wells Fargo Securities shall be 30,000 Swiss francs with joint and several liability.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT